David Jensen

Writing from the perspective of more than three decades in the news business, Jensen brings a background in business and government to bear on the $3 billion California stem cell agency. Now retired, his career included a 10-year stint as executive business editor of The Sacramento Bee, legislative coverage for United Press International and two years as a press aide to Gov. Jerry Brown during his first term in office. Jensen has covered the stem cell agency since its inception from his sailboat/home located south of the border with visits to California from time to time.

Web Site: http://californiastemcellreport.blogspot.com/


Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency

May 21, 2013
Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency

Internationally renown scientist Lee Hood, winner of a National Medal of Science, violated the conflict of interest policies of the California stem cell agency earlier this year when he was involved in reviewing applications in a $40 million round to c...

Text of CIRM Comments on Lee Hood Questions

May 21, 2013

Here is the full text of the statement today by Kevin McCormack, senior director for public communications at the California stem cell agency, in connection with the conflict of interest issue involving Lee Hood, president of Institute for Systems Biol...

Replicating Oregon Cloning in California: Views on the Legality

May 17, 2013

Oregon's stem cell cloning achievement has triggered some discussion about whether it could be replicated legally in California, which bans paying for eggs as was done in Oregon. Stanford researcher Irv Weissman said it is “not true” that Oregon...

Weissman Says Oregon-style Stem Cell Research Could be Done in California

May 17, 2013

Stanford researcher Irv Weissman says it is “not true” that Oregon's stem cell research could not be done legally in California. In a brief email to the California Stem Cell Report, he commented in connection with yesterday's item that said...

Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State

May 16, 2013

The good news out of Oregon is that some diligent scientists in the Beaver State have accomplished a major advance in stem cell research --- the cloning of human stem cells. That bad news is that their research would have been illegal in California,...

The Klein Donation: Top Stem Cell Agency Execs, Lawyers Aware of Gift but Fail to Report It

May 16, 2013

A number of top level executives, in addition to six lawyers, at the California stem cell agency knew of Robert Klein's $21,630 donation in May of last year although they failed to report it to the agency's board as required by agency regulations. ...

Klein, StemCells, Inc., and $31,000 in Consulting Fees for Torres

May 15, 2013
Klein, StemCells, Inc., and $31,000 in Consulting Fees for Torres

The Robert Klein-StemCells, Inc., affair has taken another turn with the disclosure that a vice chairman of the California stem cell agency was paid at least $31,000 over a two-year period by Klein and also voted on behalf of Klein's effort to win appr...

A Patent War on iPS: One Researcher’s View

May 14, 2013

As the California stem cell agency pushes ever more aggressively to turn research into cures, the second largest share of its awards, in terms of numbers of grants, has gone to efforts involving induced pluripotent cells, also known as reprogrammed a...

Patient Advocate Reed Defends Klein Donation to Stem Cell Agency

May 14, 2013

The California Stem Cell Report today received the following email from Don Reed, a patient advocate, who has long been involved in California stem cell agency affairs. Reed is vice president of public policy for Americans for Cures Foundation, a...

WARF hESC Patent Update: Seven Years and Challenge Still Underway

May 12, 2013

Last week UC Davis stem cell researcher Paul Knoepfler and Scripps researcher Jeanne Loring engaged in an online Q&A that touched on patents and how they can stifle research and discourage development of therapies. Loring did not mention it in t...



Newest Partners